OraSure Technologies (OSUR) vs Treace Medical Concepts (TMCI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
OraSure Technologies (OSUR) has outperformed Treace Medical Concepts (TMCI) over the past year, gaining 17.1% versus a loss of 37.1%. Over five years, OSUR leads with a -63.9% price change compared with -84.1% for TMCI. OraSure Technologies is the larger company by market cap ($261.7 million vs $252.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | OSUR | TMCI |
|---|---|---|
| Share price | $3.80 | $3.88 |
| Market cap | $261.74M | $252.01M |
| 1-day change | +1.74% | -0.39% |
| YTD return | +56.82% | +58.16% |
| 1-year return | +17.13% | -37.09% |
| 5-year return | -63.89% | -84.13% |
| EPS (TTM) | $-0.69 | $-0.92 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.58 | $7.08 |
| 52-week low | $2.08 | $1.17 |
| Distance from 52-week high | -17.14% | -45.27% |
| Analyst consensus | none | none |
| Avg. price target upside | +5.40% | +41.94% |
| Average volume | 484.72K | 330.27K |
| Shares outstanding | 68.97M | 65.03M |
| Employees | 500 | 450 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- OSUR has outperformed TMCI by 54.2 percentage points over the past year.
About OraSure Technologies
OSUR stock →OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, sells, and distributes diagnostic products and specimen collection devices in the United States, Europe, Africa, and internationally. It offers OraQuick Rapid HIV test, OraQuick HIV self-test, OraQuick HIV self-test(international), OraQuick HCV rapid antibody test and self-test, Syphilis health check rapid diagnostic test, OraQuick Ebola rapid antigen test, InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, SickleSCAN test, and OraSure oral fluid collection device for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.
Health Care · Medical/Dental Instruments · 500 employees
About Treace Medical Concepts
TMCI stock →Treace Medical Concepts, Inc., a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty System, enables surgeons to correct all three dimensions of the bunion deformity, stabilize the first TMT joint, and allow return to weight-bearing in a walking boot; minimally invasive products for four bunion classes; Nanoplasty 3D Minimally Invasive Bunion Correction System delivers a reproducible 3D correction of the bunion deformity through a cosmetically appealing; and Percuplasty Percutaneous 3D Bunion Correction System that provides 3D correction of the bunion deformity through percutaneous incisions.
Health Care · Medical/Dental Instruments · 450 employees
OSUR vs TMCI FAQ
Which is bigger, OraSure Technologies or Treace Medical Concepts?
OraSure Technologies (OSUR) is larger, with a market capitalization of $261.74M compared with $252.01M for Treace Medical Concepts (TMCI).
Which stock has performed better over the past year, OSUR or TMCI?
OSUR returned +17.13% over the past 12 months, compared with -37.09% for TMCI (price return, excluding dividends). Past performance does not predict future results.
Are OraSure Technologies and Treace Medical Concepts in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.